Cellyan Biotechnology CO Ltd (HKPD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 12-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -27 | 1,330 | N/A | 998 | N/A |
| Depreciation Amortization | 76 | 64 | N/A | 74 | N/A |
| Accounts receivable | -919 | -2,048 | N/A | -930 | N/A |
| Accounts payable and accrued liabilities | 397 | -105 | N/A | 955 | N/A |
| Other Working Capital | -520 | -2,649 | N/A | 14 | N/A |
| Other Operating Activity | 1,563 | 3,014 | 0 | 615 | 0 |
| Operating Cash Flow | $569 | $-394 | $N/A | $1,727 | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,300 | N/A | N/A | N/A | N/A |
| PPE Investments | -70 | -20 | N/A | -115 | N/A |
| Purchase Sale Intangibles | -85 | -35 | N/A | -3 | N/A |
| Other Investing Activity | -85 | -21 | 0 | -18 | 0 |
| Investing Cash Flow | $-2,455 | $-41 | $N/A | $-132 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 770 | 1,375 | N/A | N/A | N/A |
| Debt Issued | 819 | 768 | N/A | 189 | N/A |
| Debt Repayment | -1,276 | -725 | N/A | -657 | N/A |
| Common Stock Issued | 4,000 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -2,318 | -881 | 0 | -688 | 0 |
| Financing Cash Flow | $1,995 | $537 | $N/A | $-1,156 | $N/A |
| Exchange Rate Effect | 13 | 1 | N/A | 0 | N/A |
| Beginning Cash Position | 627 | 525 | N/A | 85 | N/A |
| End Cash Position | 749 | 627 | N/A | 525 | N/A |
| Net Cash Flow | $122 | $103 | $N/A | $440 | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | 569 | -394 | N/A | 1,727 | N/A |
| Capital Expenditure | -70 | -53 | N/A | -115 | N/A |
| Free Cash Flow | 499 | -447 | 0 | 1,613 | 0 |